Clinical Trials Logo

Clinical Trial Summary

Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study.


Clinical Trial Description

Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study. ;


Study Design


Related Conditions & MeSH terms

  • Chemical and Drug Induced Liver Injury

NCT number NCT04159441
Study type Observational [Patient Registry]
Source Huashan Hospital
Contact Wenhong Zhang
Phone 13801844344
Email zhangwenhong@fudan.edu.cn
Status Not yet recruiting
Phase
Start date December 5, 2019
Completion date June 5, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05014087 - Digoxin In Treatment of Alcohol Associated Hepatitis Phase 2